Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications

Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

Two new studies add to evidence that most people with type 1 diabetes are not at excessively higher risk for COVID-19 mortality than the general population.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Coronavirus does not act alone but with co-morbidities such as obesity and diabetes
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
Two new studies add to evidence that most people with type 1 diabetes are not at excessively higher risk for COVID-19 mortality than the general population.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news
Conclusion: This study will explore the effectiveness and safety of DPP-4 inhibitors in the treatment of COVID-19 patients with diabetes. It will provide evidence-based medical evidence for DPP-4 inhibitors in the treatment of diabetes with COVID-19. Registration number: INPLASY202090015.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
AbstractPurposeDiabetic ’s patients are supposed to experience higher rates of COVID-19 related poor outcomes. We aimed to determine factors predicting poor outcomes in hospitalized diabetic patients with COVID-19.MethodsThis retrospective cohort study included all adult diabetic patients with radiological or laboratory confirmed COVID-19 who hospitalized between 20 February 2020 and 27 April 2020 in Alborz province, Iran. Data on demographic, medical history, and laboratory test at presentation were obtained from electronic medical records. Diagnosis of diabetes mellitus was self-reported. Comorbidities including ca...
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
Little is known about the relationship between thyroiditis and COVID-19. How should clinicians answer patient questions about the potential risks and complications?American Thyroid Association
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
(Penn State) A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractPurpose of reviewTo elucidate the intertwining of vascular events, vascular disease and vascular risk factors and COVID-19.Recent findingsStrokes are a leading cause of disability and death worldwide. Vascular risk factors are important drivers of strokes. There are unmodifiable vascular risk factors such as age and ethnicity and modifiable vascular risk factors. According to the INTERSTROKE study, the 10 most frequent modifiable vascular risk factors are arterial hypertension, physical inactivity, overweight, dyslipidaemia, smoking, unhealthy diet, cardiac pathologies, diabetes mellitus, stress/depression and over...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
ConclusionsDespite a rapid worldwide spread, attack rates have been low in most regions, demonstrating the efficacy of control measures.
Source: Infection - Category: Infectious Diseases Source Type: research
by Mehrshad Sadria, Anita T. Layton Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are frequently prescribed for a range of diseases including hypertension, proteinuric chronic kidney disease, and heart failure. There is evidence indicating that these drugs upregulate ACE2, a key component of the renin-angiotensin system (RAS) and is found on the cells of a number of tissues, including the epithelial cells in the lungs. While ACE2 has a beneficial role in many diseases such as hypertension, diabetes, and cardiovascular disease, it also serves as a receptor for both SARS-CoV and ...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
More News: AstraZeneca | Biotechnology | Cardiology | Clinical Trials | COVID-19 | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Health Management | Heart | Urology & Nephrology | USA Health